Opportunity Information: Apply for PAR 06 449
Apply for PAR 06 449
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Paul Calabresi Career Development Award For Clinical Oncology (K12)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.398 Cancer Research Manpower.
- This funding opportunity was created on Mar 23, 2010 and posted on Jun 8, 2006.
- Applicants must submit their applications by Mar 23, 2010 Multiple Receipt Dates See Link to Full Announcement for details.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Public and State controlled institutions of higher education For profit organizations other than small businesses Private institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.
- Foreign institutions are not eligible to apply. All clinician and basic science Ph.D. scholars must satisfy the following additional requirements Special Requirements Other training programs Where there already exists an active Ruth L. Kirschstein (T32) National Research Service Award (NRSA) or other institutional career development program (e.g., NCI and NIH Roadmap K12, K30, General Clinical Research Core GCRC Scholars Program) overlap between these programs must be eliminated and/or the NCI Paul Calabresi Award for Clinical Oncology (K12) structured in a way to complement and take advantage of these other career development/training programs. This may require merging components of other programs with the NCI K12 or linking curriculum programs (e.g., K30) with the core requirements of the NCI K12. Institutions require NCI approval to submit an application if another NCI K12 exists at the institution. Institution The institution must have substantial support for peer reviewed basic science and clinical research and an adequate number of faculty qualified in patient oriented therapeutic research, translational research, and basic science cancer research to serve as mentors in the proposed Program. Environment The research environment should be one in which there are active basic science/clinical research collaborations that exemplify a dynamic two way exchange of information and ideas between basic science research and clinical scientists. Special Program Requirements Program Management The PI must use an Advisory Committee (AC) to provide an oversight function and annual evaluation of the Program as a whole. The committees responsibilities should include but are not limited to selecting clinician, nurse, and basic science scholars (Note basic science scholars are encouraged as part of these Programs but they are optional), assigning preceptors, approving each scholars career development plan, evaluating each scholars progress, authorizing the termination of a scholar who is not performing adequately, monitoring the overall effectiveness of the program and recommending mid course changes when needed. A detailed description of the committees composition, function, and frequency of meetings should be provided. See Program Announcement for more information.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Paul Calabresi Career Development Award for Clinical Oncology (K12), often referred to as the PCACO, is an NIH career development program designed to build a strong pipeline of professionals who can do patient-oriented cancer therapeutic research and who can work effectively across the clinical and basic science divide. At its core, the program is aimed at producing teams of clinicians and research scientists who can jointly create and run hypothesis-driven translational studies, meaning studies that intentionally move discoveries from the lab and prior clinical observations into well-constructed therapeutic trials in patients, with clear scientific questions being tested rather than purely descriptive or exploratory work.
The opportunity focuses on developing a cadre of medical doctors (MDs and DOs), doctorally prepared nurses (PhD or equivalent), and doctoral-level basic research scientists (PhD, DVM, or equivalent) who are committed to clinical oncology therapeutics. The training emphasis is practical and trial-centered: scholars are expected to learn how to develop scientific hypotheses grounded in fundamental and clinical findings, translate those hypotheses into clinical therapeutic protocols, and pair those protocols with relevant biological or correlative analyses. For clinician scholars in particular, the program explicitly highlights competence across the full spectrum of cancer clinical trials, including early pilot/Phase I studies, Phase II studies, and Phase III trials, so the expectation is not just exposure to research but real preparation to lead and administer therapeutic clinical trials over time.
A major theme of the K12 is team science and bidirectional translation. The program expects an environment where basic and clinical investigators routinely collaborate, exchange ideas, and iterate between mechanistic insights and patient data. This two-way flow is presented as essential to speeding up the movement of discoveries into patient-focused therapeutic research. At the same time, the announcement draws a clear boundary around what the program is not meant to do: it is not intended to train laboratory-based scientists whose work will primarily rely on animal models or other non-patient model systems as the central focus. Basic scientists can be part of the scholar pool, and their participation is encouraged, but the overall center of gravity remains clinical oncology therapeutics and translational, patient-oriented research.
Applications are submitted by an institution on behalf of a program leader (the principal investigator/program director) rather than by individual scholars. Eligible applicant organizations include a wide range of US-based public or private entities such as universities, colleges, hospitals, and laboratories, and they may be nonprofit or for-profit (with for-profit organizations other than small businesses explicitly listed as eligible). Multiple categories of nonprofits are eligible, including 501(c)(3) organizations and nonprofits without that designation, as well as public and state-controlled institutions of higher education and private institutions of higher education. Foreign institutions are not eligible to apply, and the program is framed as a domestic institutional training and career development mechanism.
The institutional and program infrastructure requirements are substantial. The institution is expected to have strong, ongoing support for peer-reviewed basic science and clinical research and enough qualified faculty to mentor scholars in patient-oriented therapeutic research, translational research, and basic science cancer research as it relates to translation into therapies. The surrounding research environment is expected to already demonstrate active collaborations between basic and clinical researchers rather than proposing collaboration as a future goal without evidence. In other words, the program is meant to be housed where translational team science is already functioning and can be leveraged to train scholars effectively.
There are also specific coordination expectations with other training and career development programs. If an institution already has an active NIH T32 NRSA program or other institutional career development programs (including other NIH or NCI K12 mechanisms, K30 programs, or similar structured scholar programs), overlap must be removed. The K12 must be structured to complement existing programs, which may involve merging pieces, linking curricula, or otherwise showing a clean division of effort and purpose. In addition, if an institution already has another NCI K12 award, the institution needs NCI approval to submit an application, reinforcing the idea that NIH does not want redundant, overlapping institutional career development structures competing for the same scholar population without clear differentiation.
Program governance is another central requirement. The principal investigator must use an Advisory Committee to oversee the program and conduct an annual evaluation of the program as a whole. This committee is responsible for core decisions such as selecting clinician, nurse, and (optionally) basic science scholars; assigning mentors or preceptors; approving each scholar's career development plan; reviewing progress; and recommending course corrections when needed. The committee also has authority to recommend termination of a scholar who is not progressing adequately, which signals that the program expects active management and accountability rather than a hands-off appointment. Applications are expected to describe the committee's composition, responsibilities, and meeting frequency in detail.
Administratively, this opportunity was issued as a Program Announcement with a funding opportunity number PAR-06-449 under NIH. It is categorized as a discretionary grant with an education and health activity focus, and it is associated with CFDA 93.398 (Cancer Research Manpower). The announcement originally posted in June 2006 and reflects multiple receipt dates rather than a single due date, with the details for submission windows provided in the full announcement. The provided record indicates an archive date in April 2010, meaning it is no longer an active solicitation in that exact form, but the summary captures the intent and structure of the program as published.
For further official details, the full announcement is linked through the NIH Grants Guide at http://grants.nih.gov/grants/guide/pa-files/PAR-06-449.html, and the NIH Office of Extramural Research webmaster contact is provided for access or technical issues related to the posting.
Frequently Asked Questions (FAQs): Paul Calabresi Career Development Award for Clinical Oncology (K12 / PCACO)
What is the Paul Calabresi Career Development Award for Clinical Oncology (K12/PCACO)?
The Paul Calabresi Career Development Award for Clinical Oncology (often called the PCACO) is an NIH K12 institutional career development program focused on building a pipeline of professionals who can conduct patient-oriented cancer therapeutic research and work effectively across clinical and basic science. The program emphasis is on hypothesis-driven translational studies that move discoveries and prior clinical observations into well-constructed therapeutic trials in patients.
What is the central purpose of this K12 program?
The core goal is to develop teams of clinicians and research scientists who can jointly design and run hypothesis-driven translational therapeutic studies in patients. The intent is not descriptive or purely exploratory research, but clinically grounded therapeutic research that tests clear scientific questions and integrates relevant biological or correlative analyses.
What kinds of research does the program emphasize?
The program emphasizes patient-oriented cancer therapeutic research and translational research that intentionally bridges laboratory discoveries and clinical observations into therapeutic trials. Scholars are expected to learn how to develop testable hypotheses, translate them into clinical therapeutic protocols, and include relevant biological/correlative components to answer the scientific questions embedded in the trial.
What does "hypothesis-driven translational studies" mean in this context?
In this program context, hypothesis-driven translational studies are therapeutic studies in patients that are designed around clear scientific hypotheses derived from fundamental and clinical findings. The studies are constructed to test those hypotheses within therapeutic clinical protocols, rather than simply collecting observations without a defined mechanistic or scientific question.
Who is the program intended to train?
The opportunity focuses on developing a cadre of: (1) medical doctors (MDs and DOs), (2) doctorally prepared nurses (PhD or equivalent), and (3) doctoral-level basic research scientists (PhD, DVM, or equivalent) who are committed to clinical oncology therapeutics.
Are basic research scientists eligible to be scholars in the program?
Yes. Doctoral-level basic research scientists (PhD, DVM, or equivalent) are included in the targeted scholar pool, and their participation is encouraged. However, the program's center of gravity remains clinical oncology therapeutics and translational, patient-oriented research.
What types of training outcomes are expected for clinician scholars?
For clinician scholars, the program explicitly highlights competence across the full spectrum of cancer clinical trials. This includes early pilot/Phase I studies, Phase II studies, and Phase III trials, with the expectation that scholars are prepared over time to lead and administer therapeutic clinical trials.
Does the program require a team science approach?
Yes. A major theme is team science and bidirectional translation. The program expects a working environment where basic and clinical investigators routinely collaborate, exchange ideas, and iterate between mechanistic insights and patient data to speed translation into patient-focused therapeutic research.
What is meant by "bidirectional translation" in the program description?
Bidirectional translation refers to the two-way flow between basic and clinical research: mechanistic insights informing patient studies, and patient data feeding back into new hypotheses and mechanistic understanding. The program positions this two-way exchange as essential to accelerating therapeutic advances.
What research focus is explicitly not the primary intent of this K12?
The announcement draws a clear boundary that it is not intended to train laboratory-based scientists whose work will primarily rely on animal models or other non-patient model systems as the central focus. While basic scientists can participate, the overall program focus remains patient-oriented, translational clinical oncology therapeutics.
Who submits the application: individual scholars or the institution?
Applications are submitted by an institution on behalf of a program leader (the principal investigator/program director). Individual scholars do not apply directly under this mechanism as described in the provided information.
What types of organizations are eligible to apply?
Eligible applicant organizations include a wide range of US-based public or private entities such as universities, colleges, hospitals, and laboratories. Organizations may be nonprofit or for-profit (with for-profit organizations other than small businesses explicitly listed as eligible). Eligible nonprofit categories include 501(c)(3) organizations and nonprofits without that designation, as well as public/state-controlled and private institutions of higher education.
Are for-profit organizations eligible to apply?
Yes. The eligibility summary explicitly includes for-profit organizations other than small businesses among eligible applicant organizations.
Can foreign institutions apply?
No. Foreign institutions are not eligible to apply. The opportunity is framed as a domestic, institutional training and career development mechanism.
What kind of institutional environment is expected for a strong application?
The institution is expected to already have strong, ongoing support for peer-reviewed basic science and clinical research, along with enough qualified faculty to mentor scholars in patient-oriented therapeutic research, translational research, and basic science cancer research as it relates to translation into therapies.
Does the program require evidence of existing basic-clinical collaborations?
Yes. The surrounding research environment is expected to demonstrate active collaborations between basic and clinical researchers. The program is intended to be housed where translational team science is already functioning, rather than proposing collaboration as a future goal without evidence.
How should institutions handle overlap with existing training or career development programs?
If an institution already has an active NIH T32 NRSA program or other institutional career development programs (including other NIH or NCI K12 mechanisms, K30 programs, or similar structured scholar programs), overlap must be removed. The K12 should be structured to complement existing programs, which may involve merging elements, linking curricula, or otherwise demonstrating a clean division of effort and purpose.
What if the institution already has another NCI K12 award?
If an institution already has another NCI K12 award, the institution needs NCI approval to submit an application, reflecting an expectation that redundant or overlapping institutional career development structures should be avoided unless clearly differentiated.
What governance structure is required for the program?
The principal investigator must use an Advisory Committee to oversee the program and conduct an annual evaluation of the program as a whole.
What does the Advisory Committee do?
The Advisory Committee is responsible for core program decisions, including selecting clinician, nurse, and (optionally) basic science scholars; assigning mentors or preceptors; approving each scholar's career development plan; reviewing scholar progress; recommending course corrections; and (when necessary) recommending termination of a scholar who is not progressing adequately.
What should an application say about the Advisory Committee?
Applications are expected to describe the Advisory Committee's composition, responsibilities, and meeting frequency in detail.
Is program evaluation required?
Yes. The program requires an annual evaluation of the program as a whole, conducted through the oversight structure (the Advisory Committee) described in the announcement summary.
What is the funding opportunity number and mechanism mentioned?
The opportunity is identified as NIH Program Announcement PAR-06-449 and is described as a K12 institutional career development program.
What is the associated CFDA number?
The opportunity is associated with CFDA 93.398 (Cancer Research Manpower).
When was this announcement posted, and is it still active?
The record indicates the announcement was originally posted in June 2006, with multiple receipt dates (rather than a single due date) described in the full announcement. The record also indicates an archive date in April 2010, meaning it is no longer an active solicitation in that exact form, though the summary reflects the published intent and structure.
Where can applicants find the official full announcement?
The full announcement is available through the NIH Grants Guide at: http://grants.nih.gov/grants/guide/pa-files/PAR-06-449.html
Who is listed as a contact for technical issues with the posting?
The NIH Office of Extramural Research webmaster contact is provided in the announcement record for access or technical issues related to the posting.
Browse more opportunities from the same category: Education Health
Next opportunity: The NCI Transition Career Development Award (K22)
Previous opportunity: Interventions And Practice Research Infrastructure Program (IP RISP) (R24)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 06 449
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 06 449) also looked into and applied for these:
| Funding Opportunity |
|---|
| The NCI Transition Career Development Award (K22) Apply for PAR 06 455 Funding Number: PAR 06 455 Agency: National Institutes of Health Category: Education Health Funding Amount: $125,000 |
| Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows (F31) Apply for PA 07 002 Funding Number: PA 07 002 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Feasibility Studies for Collaborative Interaction for Minority Institution/Cancer Center Partnership (P20) Apply for PAR 07 230 Funding Number: PAR 07 230 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12) Apply for PAR 07 346 Funding Number: PAR 07 346 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| AIDS International Training and Research Program (D43) Apply for PAR 07 348 Funding Number: PAR 07 348 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| 2009 NIDA Avant Garde Award Program for HIV/AIDS Research (DP1) Apply for RFA DA 09 011 Funding Number: RFA DA 09 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Pre Application for the 2009 NIDA Avant Garde Award Program for HIV/AIDS Research (X02) Apply for PAR 09 044 Funding Number: PAR 09 044 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Innovative and Applied Emerging Technologies in Biospecimen Science (R21) Apply for RFA CA 09 004 Funding Number: RFA CA 09 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Innovative and Applied Emerging Technologies in Biospecimen Science (R33) Apply for RFA CA 09 005 Funding Number: RFA CA 09 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Application and Use of Transformative Emerging Technologies in Cancer Research (R21) Apply for RFA CA 09 006 Funding Number: RFA CA 09 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Application and Use of Transformative Emerging Technologies in Cancer Research (R33) Apply for RFA CA 09 007 Funding Number: RFA CA 09 007 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Innovative Technology Development for Cancer Research (R21) Apply for RFA CA 09 008 Funding Number: RFA CA 09 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08) Apply for PAR 09 050 Funding Number: PAR 09 050 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI Mentored Patient Oriented Research Career Development Award to Promote Diversity (K23) Apply for PAR 09 051 Funding Number: PAR 09 051 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI Mentored Research Scientist Development Award to Promote Diversity (K01) Apply for PAR 09 052 Funding Number: PAR 09 052 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Mechanism for Time Sensitive Research Opportunities (R03) Apply for PAR 06 249 Funding Number: PAR 06 249 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Support Opportunity for Addiction Research (SOAR) for New Investigators (R03) Apply for RFA DA 09 021 Funding Number: RFA DA 09 021 Agency: National Institutes of Health Category: Education Health Funding Amount: $25,000 |
| Midcareer Investigator Award in Mouse Pathobiology Research (K26) Apply for PAR 09 053 Funding Number: PAR 09 053 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Tools for Germplasm Cryopreservation (STTR) R41/R42 Apply for PA 09 054 Funding Number: PA 09 054 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Tools for Germplasm Cryopreservation (SBIR) R43/R44 Apply for PA 09 055 Funding Number: PA 09 055 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 06 449", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.